Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Olanzapine in the Treatment of Hair Pulling (Trichotillomania)

This study has been completed.
Eli Lilly and Company
Information provided by:
McMaster University Identifier:
First received: September 14, 2005
Last updated: September 8, 2006
Last verified: March 2006
Trichotillomania (TTM) or hair-pulling has been considered as part of the obsessive compulsive disorder (OCD) spectrum, although treatment with OCD medications has largely been unsuccessful. Tics/Tourrettes’ Syndrome (TS) is a disorder, which appears to be related to TTM, but is treated with a different class of medications than used in OCD, namely antipsychotics such as olanzapine. This is a study of the safety and efficacy of olanzapine in the treatment of hair pulling.

Condition Intervention Phase
Drug: Olanzapine
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A 12-Week, Double-Blind Trial of Olanzapine and Placebo in the Treatment of Trichotillomania

Resource links provided by NLM:

Further study details as provided by McMaster University:

Primary Outcome Measures:
  • Clinical Global Impression (CGI)-Improvement Scale ≤ 2

Secondary Outcome Measures:
  • CGI-Severity Scale, Mean change from baseline in: Yale-Brown Obsessive Compulsive Scale for TTM, the Massachusetts General Hospital Hair Pulling Scale

Estimated Enrollment: 34
Study Start Date: June 2000
Estimated Study Completion Date: March 2006

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • primary DSM-IV trichotillomania; CGI-Severity ≥ 4

Exclusion Criteria:

  • Any other Axis I primary diagnosis; CGI-S < 4; current comorbid: OCD, MDD, alcohol or substance abuse; lifetime hx of: schizophrenia, bipolar affective disorder or dementia; current pregnancy/lactation; current suicidality or homicidality; major medical problems or clinically unstable medical disease; hx of: seizures, stroke or head trauma; prior use of neuroleptics
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00182507

Canada, Ontario
Hamilton Health Sciences, McMaster University Medical Centre
Hamilton, Ontario, Canada, L8N 3Z5
Sponsors and Collaborators
Hamilton Health Sciences Corporation
Eli Lilly and Company
Principal Investigator: Michael A Van Ameringen, MD, FRCPC Hamilton Health Science, McMaster Univeristy Medical Centre
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00182507     History of Changes
Other Study ID Numbers: 00-167
Study First Received: September 14, 2005
Last Updated: September 8, 2006

Additional relevant MeSH terms:
Disruptive, Impulse Control, and Conduct Disorders
Mental Disorders
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents processed this record on April 26, 2017